Current Report Filing (8-k)
May 08 2023 - 4:14PM
Edgar (US Regulatory)
0001937653falseTRUE00019376532023-05-082023-05-080001937653us-gaap:CommonStockMember2023-05-082023-05-080001937653zyme:PreferredStockPurchaseRightsMember2023-05-082023-05-08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 8, 2023 Zymeworks Inc.
(Exact name of registrant as specified in its charter) | | | | | | | | | | | | | | |
|
|
|
|
|
Delaware | | 001-41535 | | 88-3099146 |
| (State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
|
|
108 Patriot Drive, Suite A, Middletown, Delaware | | 19709 |
| (Address of principal executive offices) | | (Zip Code) |
(302) 274-8744
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | | | | |
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | | | | | | | |
|
|
|
|
|
| Title of each class | | Trading
Symbol(s) | | Name of each exchange
on which registered |
Common Stock, $0.00001 par value per share Preferred Stock Purchase Rights | | ZYME N/A | | The Nasdaq Stock Market LLC The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| | | | | |
| ITEM 2.02 | RESULTS OF OPERATIONS AND FINANCIAL CONDITION |
The following information is furnished pursuant to Item 2.02, “Results of Operations and Financial Condition.”
On May 8, 2023, Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2023. A copy of the press release is attached as Exhibit 99.1 to this Form 8-K.
The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
The Company makes reference to certain non-GAAP financial measures in the press release. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures is contained in the attached press release.
| | | | | |
| ITEM 9.01 | FINANCIAL STATEMENTS AND EXHIBITS |
(d) Exhibits | | | | | | | | |
| Exhibit No. | | Description |
|
|
| 99.1 | | |
| 104 | | Cover Page Interactive Data File (embedded as Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | |
|
| ZYMEWORKS INC. |
| (Registrant) |
| | | | | | | | | | | | | | | | | | | | |
|
|
|
|
|
|
|
Date: May 8, 2023 | |
| | By: | | /s/ Christopher Astle |
| |
| | Name: | | Christopher Astle |
| |
| | Title: | | Senior Vice President and |
| |
| |
| | Chief Financial Officer |
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Nov 2024 to Dec 2024
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Dec 2023 to Dec 2024
